Clinical Trials Logo
  1. Home
  2. Borderline Personality Disorder
  3. NCT03149926
  4. Details
NCT03149926 Clinical Trial

Emotional Reaction and Self Injury in Patients With Borderline Personality Disorder and Healthy Controls

Borderline Personality Disorder Clinical Trial

Official title:
Emotional Reaction of Patients With Borderline Personality Disorder (BPD)on Stimuli Connected to Self-injury - A Comparison Between Patients With BPD and a Healthy Control Group.

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT03149926
Other study ID # UOldenburg2
Secondary ID
Status Not yet recruiting
Phase N/A
First received May 9, 2017
Last updated May 11, 2017
Start date June 2017
Est. completion date February 2018

Study information
Verified date May 2017
Source University of Oldenburg
Contact Katharina Bachmann, Psych.Msc.
Phone 00494119615 1506
Email Katharina.Bachmann@uni-oldenburg.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The current study investigates the emotional response of patients with borderline personality disorder and healthy controls on stimuli associated with self-injury.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 60
Est. completion date February 2018
Est. primary completion date December 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Patients that are able to use skills and have some therapy experiences.

Exclusion Criteria:

- Severe psychiatric comorbidity e.g. psychosis, severe depression, suicidality

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Stimuli presentation
Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.

Locations
Country Name City State
Germany Department of Psychiatry and Psychotherapy - University Hospital, University of Oldenburg Bad Zwischenahn

Sponsors (1)
Lead Sponsor Collaborator
Katharina Bachmann

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Emotional reaction Patients comparded to healthy controls will show a stronger emotional reaction on the stimuli.
Patients more severely affected will show a stronger emotional reaction compared to less affected patients.		 one session of 90min
See also
  Status Clinical Trial Phase
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Active, not recruiting NCT04587518 - Five Factor Model Treatment for Borderline Personality Disorder N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Completed NCT03677037 - The Short-Term MBT Project Phase 3
Not yet recruiting NCT05989529 - Delving Into Borderline Personality Disorder Clinical Trial Experiences
Completed NCT02068326 - MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial N/A
Completed NCT02518906 - Evaluation of AIT Study N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Completed NCT02108990 - Acetaminophen and Social Processes Phase 2
Terminated NCT02149823 - Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Phase 1
Completed NCT02988037 - Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study N/A
Not yet recruiting NCT01683136 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder N/A
Completed NCT01635556 - Evaluation of a Modified Dialectical Behavior Therapy Program N/A
Completed NCT02397031 - Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder N/A
Terminated NCT01212588 - Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Phase 2
Terminated NCT01103180 - Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Phase 2
Terminated NCT00539188 - N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Phase 2
Recruiting NCT05398627 - Neurofeedback for Borderline Personality Disorder N/A
Recruiting NCT03994510 - SHame prOpensity in bOrderline Personality Disorder N/A
Recruiting NCT06005129 - Personality Change Study for Borderline Personality Disorder N/A